Employers did not intentionally set out to address social determinants of health, but the programs they were implementing were doing so, said Michael Thompson, president and chief executive officer of the National Alliance of Healthcare Purchaser Coalitions.
Employers did not intentionally set out to address social determinants of health, but the programs they were implementing were doing so, said Michael Thompson, president and chief executive officer of the National Alliance of Healthcare Purchaser Coalitions.
Transcript
Are employers starting to get a handle on how to address social determinants of health?
What’s interesting is that I don’t think employers intended to get at “social determinants of health” when they’ve implemented some of the programs they’ve implemented. What they’ve found though is when they implement programs that are based on advocacy, actually getting to know what’s going on in somebody’s life and supporting them to get the healthcare and improve the health behaviors that they have, they actually end up finding underlying causes that, if addressed, achieve that broader goal.
And so, the success of these programs, and they’ve had quite a good track record, is a much more holistic view on how to help employees and their families. And, while it’s not changing the social determinants from a societal standpoint, it is better understanding the underlying issues in an individual’s life that is impacting their overall health and well-being.
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
2 Commerce Drive
Cranbury, NJ 08512